I still remember in @Zuzalu_city 2023 there was this peculiar situation: On the one side of the harbour was an AI conference, and the mood was AI is gonna destroy us all. On the other side of the harbour I was running a life extension conference under the @vitadao umbrella and the mood was: we all gonna make it and live a very long time. A little conundrum. Interesting how the narrative has changed to we are all only gonna live a very long time because AI will accelerate biotech. I’m not sure if I’d agree with that, but it seems that this is the vibe. That being said the main obstacles for AI accelerating progress in aging biology are: 1.) We don’t have useful large scale datasets to train the AIs. At @TTIScience we are building new tools and large scale evolutionary and embryonic dataset to learn the secrets of rejuvenation from nature. But other datasets are also needed, especially human ones. 2.) A lot of obstacles are regulatory @JackScannell13 has been thinking about this quite in depth and @RuxandraTeslo recently wrote a good article on this. And it’s questionable how useful AI is there. Currently on average we get ~50 FDA approved drugs a year. If AI is really the panacea we should see double that amount per year in the next 5 years, and be well in the thousands in the next 10 years. Will be easy to track.